Dose selection for glycopyrrolate/eFlow(®) phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies

Benzer Materyaller

• In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution
  Yazar:: Pham, Stephen, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Efficacy and Safety of Nebulized Glycopyrrolate/eFlow® Closed System in Patients with Moderate-to-Very-Severe Chronic Obstructive Pulmonary Disease with Pre-Existing Cardiovascular Risk Factors
  Yazar:: Ferguson, Gary T., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
  Yazar:: Ohar, Jill, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN Studies
  Yazar:: Ferguson, Gary T., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies
  Yazar:: Donohue, James F, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)